Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<jats:p>We have evaluated the influence of age and immunization routes for induction of HIV-1- and<jats:italic>M. tuberculosis</jats:italic>-specific immune responses after neonatal (7 days old) and adult (7 weeks old) BALB/c mice immunization with BCG.HIVA<jats:sup>222</jats:sup>prime and MVA.HIVA boost. The specific HIV-1 cellular immune responses were analyzed in spleen cells. The body weight of the newborn mice was weekly recorded. The frequencies of HIV-specific CD8<jats:sup>+</jats:sup>T cells producing IFN-γ were higher in adult mice vaccinated intradermally and lower in adult and newborn mice vaccinated subcutaneously. In all cases the IFN-γ production was significantly higher when mice were primed with BCG.HIVA<jats:sup>222</jats:sup>compared with BCGwt. When the HIV-specific CTL activity was assessed, the frequencies of specific killing were higher in newborn mice than in adults. The prime-boost vaccination regimen which includes BCG.HIVA<jats:sup>222</jats:sup>and MVA.HIVA was safe when inoculated to newborn mice. The administration of BCG.HIVA<jats:sup>222</jats:sup>to newborn mice is safe and immunogenic and increased the HIV-specific responses induced by MVA.HIVA vaccine. It might be a good model for infant HIV and Tuberculosis bivalent vaccine.</jats:p>

Original publication




Journal article


Clinical and Developmental Immunology


Hindawi Limited

Publication Date





1 - 11